Multiple myeloma patients experience high response rate with new 3-drug combination

NEW ORLEANS -- A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute. Link:  http://www.dfci.harvard.edu

Read the whole article on Science Blog

More from Science Blog